PQQ for Health & Longevity

Evidence Review created on 10/09/2026 using AI4L / Opus 5.5

Also known as: Pyrroloquinoline Quinone, Methoxatin, Pyrroloquinoline Quinone Disodium Salt, PQQ Disodium Salt, BioPQQ, MGCPQQ, mnemoPQQ, PureQQ

Motivation

Pyrroloquinoline quinone (PQQ) is a small compound made by soil bacteria and present in trace amounts in foods such as fermented soybeans, green tea, parsley and kiwi, as well as in human breast milk. It is sold as a dietary supplement on the idea that it helps cells build and maintain their energy-producing compartments, and the decline of these compartments is one of the recognized features of aging.

Interest grew after researchers in the late 1980s studied mice raised on diets lacking PQQ, which started a long-running debate over whether it should count as a vitamin. Supplement makers now promote it mainly for memory, mental energy and healthy aging, and a series of small trials has tested it in healthy middle-aged and older adults.

This review examines the human, animal and laboratory evidence on PQQ for health and longevity: its proposed effects on brain function, physical performance and metabolism, its safety record including findings from high-dose animal studies, practical dosing and monitoring, and how much of the research is funded by companies that sell it.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Pyrroloquinoline quinone

An encyclopedia-style entry covering PQQ chemistry, bacterial biosynthesis, the vitamin-status debate and mitochondrial claims; useful orientation, although it notes that most evidence is preclinical and covers only a few small human trials.

Examine

PQQ benefits, dosage, and side effects

Examine’s independent summary notes that PQQ was once thought to be a vitamin, shows limited human evidence (two trials with 27 participants in its research snapshot) and outlines dosing; detailed grades require a subscription.

ConsumerLab

Pyrroloquinoline Quinone (PQQ) Supplements Review and Top Picks

Independent laboratory testing found that two of seven PQQ supplements contained less PQQ than labeled; the review also summarizes the human evidence. ConsumerLab earns membership revenue, and full results require a paid membership.

Systematic Reviews

No systematic reviews or meta-analyses for PQQ were found on PubMed as of October 9, 2026.

Neither the claimed cognitive benefit nor the principal risk (kidney effects at high doses in rats) is therefore represented by a systematic review or meta-analysis.

Mechanism of Action

PQQ is a redox-cycling molecule (it repeatedly accepts and donates electrons) that bacteria use as an enzyme helper; no human enzyme has been confirmed to require it. Three overlapping explanations for its effects compete:

Making new mitochondria: In mouse liver cells, PQQ activated CREB (a protein switch that turns on genes) and PGC-1α (the master regulator of mitochondrial production) (Chowanadisai et al., 2010). At nanomolar concentrations it raised NAD⁺ (nicotinamide adenine dinucleotide, a cellular energy carrier) and activated SIRT1 (sirtuin 1, an NAD⁺-dependent enzyme that tunes metabolism) (Saihara et al., 2017, co-authored by Mitsubishi Gas Chemical, maker of BioPQQ).
Antioxidant signaling: PQQ neutralizes reactive oxygen species (unstable, damaging oxygen molecules) and activates Nrf2 (nuclear factor erythroid 2-related factor 2, the master antioxidant switch) in aging mouse bone (Li et al., 2023).
Brief beneficial stress: In worms, lifespan extension required PQQ to generate small amounts of hydrogen peroxide (Sasakura et al., 2017, with Mitsubishi Gas Chemical co-authors), the opposite of a pure antioxidant action.

Pharmacology: blood levels of oral PQQ disodium salt peak about 2–3 hours after a dose and fall to trace levels by 24 hours; no formal half-life has been published (manufacturer review by Ikemoto et al., 2024). In mice about 62% of a dose is absorbed and about 81% of that leaves in urine, with the kidney retaining the most (European Food Safety Authority (EFSA), 2017). No receptor selectivity or CYP (cytochrome P450, liver drug-metabolizing enzymes) pathway has been identified.

Historical Context & Evolution

PQQ was discovered around 1979 as a cofactor of bacterial enzymes that oxidize alcohols and sugars for energy, as recounted in a historical review by Duine, 1999, which also argued that hopes for PQQ as a vitamin had diminished because only bacteria make it. Interest in mammals began when mice fed a purified diet lacking PQQ grew poorly, reproduced badly and developed fragile skin, suggesting a growth-factor or vitamin role (Killgore et al., 1989).

In 2003 a Nature report proposed PQQ as a new vitamin, based on a mouse enzyme whose sequence resembled PQQ-binding proteins (Kasahara & Kato, 2003). Two 2005 replies challenged this: one argued the sequence motif does not indicate PQQ binding (Felton & Anthony, 2005), and the original deficiency group found that PQQ status did not alter the proposed lysine-breakdown markers (Rucker et al., 2005). The deficiency findings still stand, but no required mammalian enzyme has been confirmed, so PQQ is now usually called “vitamin-like.”

Attention then shifted to cell signaling after a 2010 report that PQQ triggers mitochondrial production in mouse cells (Chowanadisai et al., 2010). Mitsubishi Gas Chemical commercialized a fermentation-derived salt (BioPQQ); PQQ supplements have been sold in the United States since 2008 (ConsumerLab), and in 2017 EFSA judged 20 mg/day safe for healthy adults other than pregnant or breastfeeding women (EFSA, 2017). Most human trials since have been funded or co-authored by ingredient makers, so the field’s evolution has been shaped largely by commercial research rather than independent replication.

Expected Benefits

High 🟩 🟩 🟩

Cognitive Function in Healthy Middle-Aged and Older Adults ⚠️ Conflicted

Placebo-controlled trials from two separate manufacturer-linked groups reported better memory, attention or processing speed after 8–12 weeks of 20–21.5 mg/day: Itoh et al., 2016 and Tamakoshi et al., 2023 (Mitsubishi Gas Chemical), and Shiojima et al., 2022 (Ryusendo; 58 adults, plus dementia-screening gains). Proposed mechanism: more prefrontal blood flow (Nakano et al., 2016, Mitsubishi Gas Chemical). Hydrogen plus PQQ improved orientation in mild cognitive impairment (Baltic et al., 2024, maker co-authored); PQQ alone only trended in another trial (manufacturer review). Net: consistent small, industry-funded signals without independent replication.

Magnitude: Direction and conditions only: test scores improved versus placebo after 8–12 weeks at 20–21.5 mg/day, with one trial’s gain on one test confined to lower baseline scorers; the cited reports give p-values (the probability that a difference arose by chance) but no between-group effect size.

Medium 🟩 🟩

No benefit reaches Medium: beyond cognition, the controlled human trials found only borderline or subgroup-limited effects, and the other human data come from open-label (participants knew they were taking PQQ) or uncontrolled studies.

Low 🟩

Low-Density Lipoprotein (LDL) Cholesterol ⚠️ Conflicted

A Mitsubishi Gas Chemical-sponsored trial of 29 adults found a borderline fall in LDL (“bad” cholesterol) at 20 mg/day, significant only in 11 people starting at 140 mg/dL or more; a 3-day study found no change. Net: the full-sample comparison missed significance, so the effect is unconfirmed.

Magnitude: At 12 weeks LDL changed −9.1 mg/dL with PQQ versus +3.7 mg/dL with placebo (p = 0.052; 14 versus 15 participants).

Sleep, Mood and Fatigue

An open-label study of 17 adults taking 20 mg/day for 8 weeks (Nakano et al., 2012, Mitsubishi Gas Chemical) reported better sleep onset, sleep duration and waking alertness, plus improved mood and fatigue scores, as summarized in a manufacturer review. Without a placebo group, expectation effects cannot be excluded.

Magnitude: The Pittsburgh Sleep Quality Index (Japanese version) global score fell from 10.0 to 6.4 after 8 weeks, where higher scores mean worse sleep (no control group; 17 adults).

Skin Barrier Function ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

In a placebo-controlled trial of women with dry skin (Mitsubishi Gas Chemical), 20 mg/day reduced forearm water loss at 4 weeks, but skin hydration and facial measures did not change. This bears on skin comfort and appearance; net: a narrow, inconsistent signal.

Magnitude: The change in forearm TEWL (transepidermal water loss, water evaporating through skin) differed from placebo at 4 weeks only (p < 0.05; 11 versus 8 women); the paper reports this graphically without a numeric between-group figure.

Speculative 🟨

Mitochondrial Biogenesis

PQQ increased mitochondrial number in mouse cells. In a human training trial of 23 men funded by PQQ seller Nascent Health Sciences, it raised muscle PGC-1α, an unvalidated marker, without improving VO₂peak (peak aerobic fitness).

Lower Inflammatory Markers

In 10 adults, about 0.3 mg/kg daily for 3 days lowered CRP (C-reactive protein, a blood inflammation marker) and IL-6 (interleukin-6, an inflammatory signaling protein). Neither is a validated outcome surrogate; no placebo-controlled replication exists.

Lifespan and Healthspan Extension

PQQ extended lifespan in worms and midlife survival in fast-aging mice, both with Mitsubishi Gas Chemical co-authors. No normal-lifespan mammal or human longevity data exist.

Neuroprotection

PQQ blocked clumping of α-synuclein, the protein that aggregates in Parkinson’s disease, in a test tube. No trial in people with neurodegenerative disease has been reported.

Heart Protection After Blocked Blood Flow

In rats, PQQ injected around a blocked, then reopened heart artery roughly halved heart-muscle damage. Injection differs from oral use, and no human heart data exist.

Fatty Liver Protection

In obese mouse offspring, PQQ given around birth reduced liver fat, oxidative stress and liver inflammation, with effects persisting after it was stopped. No human liver data exist.

Bone and Spine Aging

Long-term dietary PQQ reduced age-related bone loss and disc degeneration in mice through Nrf2 activation. No human bone or spine data exist.

Muscle Strength in Aging

In aged mice, dietary PQQ reduced age-related muscle loss and weakness (Mitsubishi Gas Chemical authors). A Ryusendo-funded human strength trial listed by ConsumerLab could not be retrieved, so it is not graded here.

Ovarian Reserve ⚠️ Conflicted

PQQ restored ovarian reserve in chemotherapy-treated rats. An uncontrolled study (ROHTO Pharmaceutical co-authors) of 20 mg/day for 90 days found no change in AMH (anti-Müllerian hormone, an egg-supply marker). Net: no human benefit shown.

Benefit-Modifying Factors

Genetic polymorphisms: No gene variant has been studied as a modifier of PQQ’s benefits; carriers of risk variants such as APOE4 (apolipoprotein E4, a variant of a gene that makes a cholesterol-carrying protein, raising Alzheimer’s risk) have not been analyzed separately in any trial.
Baseline biomarkers: In one trial, only people with lower baseline scores on one cognitive test improved (Itoh et al., 2016), and the LDL fall was confined to those starting at 140 mg/dL or more (Nakano et al., 2015).
Sex: No trial has analyzed benefits by sex; most cognitive trials enrolled both men and women, while the skin trial enrolled only women and the endurance trial only men.
Pre-existing conditions: Trials enrolled healthy adults; the only trial in mild cognitive impairment tested a hydrogen-PQQ mixture (Baltic et al., 2024, co-authored by its maker), so benefits in disease states are unknown.
Age: Adults aged 20–40 improved cognitive flexibility by 8 weeks, whereas those aged 41–65 improved memory only at 12 weeks (Tamakoshi et al., 2023); trials included participants up to about 80 years.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no adverse event has been documented in placebo-controlled human trials, which were small, lasted at most 24 weeks and were not designed to assess kidney function.

Medium 🟥 🟥

No risk reaches Medium: the main harm signal, kidney injury, comes from rat studies at doses far above human intake rather than from human data.

Low 🟥

Headache, Insomnia and Gastrointestinal Discomfort ⚠️ Conflicted

Consumer and retailer reports list headache, insomnia and gastrointestinal discomfort, but placebo-controlled trials at 20–21.5 mg/day recorded no adverse events (Shiojima et al., 2022; Itoh et al., 2016). Net: controlled data do not support these effects at usual doses.

Magnitude: No adverse events occurred in either the PQQ or the placebo group in trials of 41–64 participants; the anecdotal reports have no comparison group and give no rates.

Blunting of Training Adaptations ⚠️ Conflicted

Antioxidant supplements can dampen the oxidative signals that drive fitness gains. In the only PQQ endurance trial, VO₂peak rose equally with 20 mg/day or placebo. Net: no blunting seen, but only in one 6-week study.

Magnitude: Direction and conditions only: VO₂peak and test duration improved after training irrespective of group, with no between-group difference (p > 0.05; 23 men); the published summary gives no outcome figure.

Speculative 🟨

Kidney Injury at High Doses

Rats developed urinary crystals and protein at 200 mg/kg/day, EFSA’s critical effect, and kidney tubule damage at 768 mg/kg/day (EFSA, 2017). This is animal data; human trials were not designed to assess kidney function.

Nerve-Cell Toxicity at High Concentrations

PQQ damaged cultured mouse neurons at 10 µM or more (Peng et al., 2020). That is far above the nanomolar blood levels after 20 mg doses, and EFSA judged pro-oxidant risk negligible there (EFSA, 2017).

Genotoxicity ⚠️ Conflicted

Weak chromosome damage appeared in one hamster cell line (Nakano et al., 2013, Mitsubishi Gas Chemical). Human-cell and live-mouse tests were negative. Net: no genotoxicity in living animals, matching EFSA’s view.

Risk-Modifying Factors

Genetic polymorphisms: No gene variant is known to alter PQQ handling or side effects, and no study has examined how genes affect its handling.
Baseline kidney function: Absorbed PQQ leaves mainly through urine and kidney injury was the critical high-dose finding, so reduced eGFR (estimated glomerular filtration rate, the kidneys’ filtering capacity) is the main theoretical risk modifier.
Sex: In rats, urinary crystals appeared in both sexes, but kidney weight gain and shrinkage of the kidney’s filtering tubules appeared only in high-dose females (EFSA, 2017); no sex difference in human tolerability has been reported.
Pre-existing conditions: Chronic kidney disease, kidney stones, pregnancy and breastfeeding are untested; EFSA’s safety conclusion covers healthy adults only (EFSA, 2017).
Age: Older adults have lower average kidney function and take more medications; a trial including participants up to about 80 years reported no adverse events but lasted only 12 weeks (Shiojima et al., 2022).

Key Interactions & Contraindications

NSAIDs (non-steroidal anti-inflammatory drugs: ibuprofen, naproxen, high-dose aspirin) — Monitor (theoretical): Regular use strains the kidneys, the organ affected by high-dose PQQ in rats; the combination could add kidney stress. Mitigation: limiting daily high-dose use alongside PQQ and checking creatinine.
Other kidney-toxic prescription drugs — Caution (theoretical): Aminoglycoside antibiotics (gentamicin), calcineurin inhibitors (transplant immune suppressants: cyclosporine, tacrolimus) and lithium could cause additive kidney injury. Mitigation: avoiding PQQ or monitoring creatinine and urinalysis more often.
Statins (cholesterol-lowering drugs: atorvastatin, rosuvastatin) — Monitor (theoretical): A possible small additive LDL reduction; no harmful interaction is expected or reported. Mitigation: rechecking lipids after 12 weeks.
Chemotherapy and radiotherapy (doxorubicin, cyclophosphamide, radiation) — Caution (theoretical): Antioxidants could in theory reduce oxidative tumor killing. Mitigation: pausing PQQ during cancer treatment unless the oncology team agrees.
Coenzyme Q10 (CoQ10) — Compatible, possibly additive (human data): Combined 20 mg PQQ with 300 mg CoQ10 improved memory, whereas PQQ alone only trended, with no reported adverse interaction (manufacturer review by Ikemoto et al., 2024). Mitigation: none needed.
Nicotinamide mononucleotide (NMN) — No interaction found (human data): A randomized single-dose trial gave 20 mg PQQ with 300 mg NMN; only the PQQ-alone group improved significantly on one interoception (sensing of internal body signals) measure; no adverse interaction was described. Mitigation: none needed.
Vitamin C — Compatible (theoretical): Vitamin C converts PQQ to its reduced, radical-scavenging form PQQH2 in a buffer solution (Mitsubishi Gas Chemical co-author), which may sustain its antioxidant cycling; clinical relevance is unknown. Mitigation: none needed.
Other antioxidant and mitochondrial supplements (alpha-lipoic acid, L-carnitine, N-acetylcysteine) — Monitor (theoretical): Overlapping antioxidant effects could add to any blunting of training adaptations. Mitigation: keeping high-dose antioxidant stacks away from training sessions.
Endurance training (other intervention) — No interaction found (human data): 20 mg/day did not reduce VO₂peak gains from 6 weeks of training (Hwang et al., 2020).

Populations who should avoid PQQ:

Pregnant or breastfeeding women: excluded from the intended use that EFSA judged safe (EFSA, 2017)
Children: EFSA notes that PQQ supplements are not intended for children (EFSA, 2017)
People with chronic kidney disease or reduced kidney function (theoretical; no source gives a numeric threshold)

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

Daily dose cap of 20 mg: EFSA’s safety conclusion covers up to 20 mg/day, a 344-fold margin below the rat no-adverse-effect level (EFSA, 2017); staying within it limits the kidney risk seen at high doses.
Kidney testing at baseline and 3 months: Serum creatinine, eGFR and urinalysis before starting and after 3 months detect early kidney strain, the main theoretical risk.
Stopping signal for worsening kidney markers: No source gives a PQQ-specific threshold; stopping at a sustained fall in eGFR from one’s own baseline or new urinary protein prevents continued exposure if kidney injury develops.
Third-party-tested products: ConsumerLab found two of seven products under-dosed (ConsumerLab); ConsumerLab, USP (United States Pharmacopeia) or NSF International certification reduces under-dosing and contamination risk.
Morning dosing: Taking PQQ in the morning avoids the insomnia occasionally described in consumer accounts.
Antioxidant stacks kept away from training: Taking PQQ and other antioxidants apart from workouts reduces the theoretical risk of blunted training adaptations.
Avoidance during pregnancy and breastfeeding: Prevents untested exposure of the fetus or infant.

Therapeutic Protocol

Each dose below is cited to its source; timing, cycling and titration reflect common practice.

Standard dose: 20 mg/day of PQQ disodium salt, the dose in most cognitive trials (Itoh et al., 2016; Tamakoshi et al., 2023) and the maximum intake EFSA assessed (EFSA, 2017).
Alternative doses: 21.5 mg/day of mnemoPQQ (Shiojima et al., 2022); about 0.3 mg/kg/day (Harris et al., 2013); 5–40 mg per serving in commercial products (ConsumerLab), the upper end exceeding EFSA’s assessed intake.
Combination regimen: 20 mg PQQ with 300 mg CoQ10 daily, tested by Mitsubishi Gas Chemical (manufacturer review by Ikemoto et al., 2024) and promoted by Life Extension, which sells both (Marcone).
Food-first alternative: Natto, green tea, parsley and kiwi supply nanogram-per-gram amounts (Kumazawa et al., 1995); a 20 mg/day dose provides at least 250 times typical dietary intake (EFSA, 2017).
Popularizers: Mitsubishi Gas Chemical (BioPQQ), Ryusendo (mnemoPQQ) and Life Extension have driven interest; no longevity clinic has published a distinct protocol.
Time of day: Morning, with or without breakfast; trials did not compare timing.
Half-life: No formal half-life exists; levels peak at 2–3 hours, fall to trace by 24 hours, and daily intake raises baseline levels (manufacturer review by Ikemoto et al., 2024).
Single or split dose: All trials used once-daily dosing; split dosing is untested.
Genetic polymorphisms: No variant is known to influence dose choice, and no data on gene effects on dosing exist.
Sex: No sex-specific dosing data exist; trials used the same dose for men and women.
Age: Adults aged 20–40 responded by 8 weeks and 41–65 by 12 weeks at 20 mg (Tamakoshi et al., 2023); adults aged 40–80 improved at 21.5 mg (Shiojima et al., 2022); age-related kidney decline is untested.
Baseline biomarkers: Lower baseline scores on one cognitive test (in one trial) and LDL of 140 mg/dL or more predicted larger responses in the trials cited above.
Pre-existing conditions: Reduced kidney function argues against use; mild cognitive impairment has been tested only with a hydrogen-PQQ mixture.

Discontinuation & Cycling

Intended duration: Human data cover at most 24 weeks; PQQ is used as an open-ended daily supplement, but no lifelong safety or benefit data exist.
Withdrawal effects: None have been reported after stopping in any trial.
Tapering: Not needed; PQQ can be stopped at once.
Cycling: No study has tested cycling; in the CoQ10 combination trial, memory gains seen at 8 weeks had faded by 24 weeks (manufacturer review by Ikemoto et al., 2024); some users cycle 12 weeks on, 4 weeks off.
Reassessment: A review at 12 weeks, matching the trial length, is common practice before deciding to continue.

Sourcing and Quality

Chemical form: Supplements use PQQ disodium salt, a reddish-brown powder made by bacterial fermentation (BioPQQ uses Hyphomicrobium denitrificans) or chemical synthesis; EFSA’s assessed product had at least 99% purity (EFSA, 2017).
Label accuracy: ConsumerLab found that two of seven tested products contained less PQQ than claimed, while none contained excess lead, cadmium or arsenic (ConsumerLab).
What to look for: Third-party certification (ConsumerLab, USP, NSF), a stated dose of PQQ disodium salt, and a named branded ingredient such as BioPQQ, mnemoPQQ or PureQQ.
Brands: Doctor’s Best (with BioPQQ), Jarrow Formulas, Life Extension and Swanson were among products ConsumerLab tested; pass or fail results are available only to members.
Combination products: CoQ10-plus-PQQ products often contain 10 mg PQQ or less; a label listing each ingredient’s dose allows comparison with trial doses.

Practical Considerations

Time to effect: Cognitive changes appeared after 8–12 weeks in trials; no immediate effect on energy or focus has been shown in controlled studies.
Common pitfalls: Expecting an immediate energy boost, taking 40 mg products above EFSA’s assessed intake, and treating worm and mouse lifespan results as evidence for humans.
Regulatory status (United States): Sold as a dietary supplement; FDA (Food and Drug Administration) raised no questions about a notice that PQQ disodium salt is generally recognized as safe in beverages at up to 8 mg per serving (FDA response letter, 2016).
Regulatory status (Europe): EFSA concluded that 20 mg/day is safe for healthy adults, excluding pregnant and breastfeeding women (EFSA, 2017).
Funding structure: PQQ is an inexpensive, unpatented supplement that insurers do not cover, so no payer or drug company funds large outcome trials; ingredient makers fund most research, a structural source of bias.

Interaction with Foundational Habits

Sleep: Possibly potentiating: an open-label study reported better sleep onset and duration with 20 mg/day, but no controlled sleep trial exists and the mechanism is unknown. Morning dosing is common practice for those who notice restlessness.
Nutrition: Indirect: foods such as natto, green tea, parsley and kiwi supply only trace PQQ, so diet cannot match supplement doses. PQQ is not known to deplete nutrients; trials gave it with or without food.
Exercise: None to neutral: 20 mg/day neither enhanced nor blunted aerobic fitness gains from endurance training, though it raised muscle PGC-1α (Hwang et al., 2020). Timing around workouts has not been studied.
Stress management: Possibly potentiating, indirect: an open-label study showed lower tension-anxiety and fatigue scores, and its sleep-score gains tracked changes in the morning rise of cortisol (the main stress hormone); no placebo-controlled stress study exists.

Monitoring Protocol & Defining Success

Before starting, a baseline panel establishes kidney function and the markers PQQ might change: serum creatinine with eGFR, a urinalysis for protein, an LDL cholesterol test, an optional hs-CRP (high-sensitivity C-reactive protein) test, and a computerized cognitive test taken at a consistent time of day. Baseline kidney testing matters most, because kidney injury is the critical finding in high-dose rat studies and no human trial was designed to assess kidney function.

Ongoing monitoring repeats the kidney tests and LDL at 3 months, then every 6–12 months while PQQ is continued; the cognitive test is repeated at 12 weeks, the time point at which trials reported changes. A rise in creatinine, a fall in eGFR or new urinary protein is a reason to stop, while unchanged cognitive scores after 12 weeks suggest no personal benefit.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Serum creatinine (with eGFR)	0.7–1.3 mg/dL in men; 0.6–1.1 mg/dL in women (standard reference range)	Safety check: a rise stops use	Kidney toxicity is the critical high-dose endpoint in rats (EFSA, 2017); heavy exercise and large meat meals in the 24 hours before testing can raise results.
Urinalysis (protein)	Negative (standard reference range)	Safety check: new protein stops use	Rats showed urinary protein and crystals at 200 mg/kg/day (EFSA, 2017); a first-morning sample is preferred.
LDL cholesterol	Below 100 mg/dL (NCEP ATP III “optimal” category)	Expected to change: possible small fall	NCEP ATP III is the National Cholesterol Education Program Adult Treatment Panel III (Expert Panel, 2001); conventional reference range on most U.S. lab reports: 0–99 mg/dL; fasting 9–12 hours improves comparability.
hs-CRP	Below 1.0 mg/L (AHA/CDC “low risk” category; AHA’s membership earns no direct revenue from this category)	Expected to change: possible fall	AHA/CDC are the American Heart Association and Centers for Disease Control and Prevention (Pearson et al., 2003); conventional reference range for hs-CRP on many U.S. lab reports: 0–3.0 mg/L; an infection in the previous 2 weeks can raise results.
Computerized cognitive test score	No established target; track change from own baseline	Expected to change: memory and attention	The same test battery at the same time of day improves comparability; practice effects can inflate repeat scores.

Qualitative markers to track:

Word recall and mental sharpness in daily tasks
Sleep onset, sleep duration and morning alertness
Daytime energy and fatigue
Mood and sense of stress
Exercise tolerance and recovery
Headache, gastrointestinal discomfort or restlessness after dosing

Emerging Research

Schizophrenia cognition trial (ongoing): NCT07393464 will randomize 70 adults with chronic schizophrenia to add-on PQQ or placebo, measuring cognition and negative symptoms (reduced motivation and emotional expression); not yet recruiting, completion expected April 2028. A positive result would extend the cognitive signal to a clinical group; a null result would weaken it.
Fat oxidation in athletes (completed, no results): NCT07148726, a 24-person placebo-controlled trial of 20 mg/day for six weeks at the University of Padova, completed in August 2025 with no results posted. A positive result would add an independent metabolic signal; a null result would further weaken exercise claims.
Combination cognition trial (completed, no results): NCT06748989 tested a product combining PQQ, GABA (gamma-aminobutyric acid, a calming brain messenger), caffeine and B vitamins in 70 postmenopausal women; completed June 2026, no results posted. Any result cannot be attributed to PQQ alone.
Hydrogen-PQQ in mild cognitive impairment: Baltic et al., 2024 reported better orientation scores but no significant BDNF (brain-derived neurotrophic factor, a nerve-growth protein) difference versus placebo; its registration (NCT05910047) lists a different primary outcome, and PQQ was not tested alone.
Glaucoma combinations: A crossover trial (Rossi et al., 2025; each patient took both products in turn) of citicoline, homotaurine, vitamin B3 and 5 mg PQQ in glaucoma found better retinal nerve-signal measures with the combination than with citicoline alone; NCT07861243 (44 participants) completed in February 2026 without posted results. PQQ’s own contribution cannot be separated.
Mammalian lifespan: PQQ extended midlife survival in short-lived senescence-accelerated mice (Odera et al., 2026, Mitsubishi Gas Chemical co-authors); independent testing in normal-lifespan mice could strengthen or overturn this.
Ovarian aging: Positive rat data (Liu et al., 2025) contrast with an uncontrolled human study (Tsuji et al., 2026) showing no AMH change; a placebo-controlled trial would clarify whether PQQ affects reproductive aging.
Bone and spine aging: Mouse studies show protection of bone (Li et al., 2023) and spinal discs (Xue et al., 2024); no human bone-density or spine trial has been registered.

Conclusion

PQQ is a compound made by bacteria, found in small amounts in food and sold as a supplement on the idea that it helps cells build and protect their energy-producing parts. For health-focused adults weighing it as a longevity tool, the evidence is thinner than the marketing.

The most consistent human signal is a modest improvement on memory and attention tests in healthy middle-aged and older people over two to three months, seen in several small trials against an inactive substitute, while another found only a possible chance effect. The only exercise trial found no fitness gain. Effects on cholesterol, sleep, mood, skin and inflammation rest on single small studies or studies without a comparison group, and the most striking results, such as longer life and healthier bones, come from worms, mice and cell cultures.

At the usual dose, human trials have documented no side effects, and European food-safety regulators judged 20 mg a day safe for healthy adults other than pregnant or breastfeeding women. The open question is the kidney: high doses harmed rat kidneys, human studies were not designed to assess kidney function, and none lasted beyond six months.

The evidence base carries a clear conflict of interest: companies that make and sell PQQ ingredients funded or co-wrote nearly all human trials and much of the animal aging work, and several popular articles promoting PQQ come from businesses that sell it. The heart association behind one monitoring benchmark earns nothing directly from it.

Top - Benefits - Risks - Protocol

PQQ for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

High 🟩 🟩 🟩

Cognitive Function in Healthy Middle-Aged and Older Adults ⚠️ Conflicted

Medium 🟩 🟩

Low 🟩

Low-Density Lipoprotein (LDL) Cholesterol ⚠️ Conflicted

Sleep, Mood and Fatigue

Skin Barrier Function ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

Speculative 🟨

Mitochondrial Biogenesis

Lower Inflammatory Markers

Lifespan and Healthspan Extension

Neuroprotection

Heart Protection After Blocked Blood Flow

Fatty Liver Protection

Bone and Spine Aging

Muscle Strength in Aging

Ovarian Reserve ⚠️ Conflicted

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Medium 🟥 🟥

Low 🟥

Headache, Insomnia and Gastrointestinal Discomfort ⚠️ Conflicted

Blunting of Training Adaptations ⚠️ Conflicted

Speculative 🟨

Kidney Injury at High Doses

Nerve-Cell Toxicity at High Concentrations

Genotoxicity ⚠️ Conflicted

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion